Saroglitazar
Star1
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- Saroglitazar
- DrugBank Accession Number
- DB13115
- Background
Saroglitazar has been investigated for the treatment of Fatty Liver.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 439.57
Monoisotopic: 439.181729592 - Chemical Formula
- C25H29NO4S
- Synonyms
- Saroglitazar
- Saroglitazarum
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Product Ingredients
Ingredient UNII CAS InChI Key Saroglitazar magnesium K8V5DLS63R 1639792-20-3 UJYFZCVPOSZDMK-YPPDDXJESA-L - International/Other Brands
- Lipaglyn
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as phenylpyrroles. These are polycyclic aromatic compounds containing a benzene ring linked to a pyrrole ring through a CC or CN bond.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Pyrroles
- Sub Class
- Substituted pyrroles
- Direct Parent
- Phenylpyrroles
- Alternative Parents
- Phenylpropanoic acids / Thiophenol ethers / Phenoxy compounds / Phenol ethers / Alkyl aryl ethers / Alkylarylthioethers / Heteroaromatic compounds / Sulfenyl compounds / Azacyclic compounds / Carboxylic acids show 6 more
- Substituents
- 2-phenylpyrrole / 3-phenylpropanoic-acid / Alkyl aryl ether / Alkylarylthioether / Aromatic heteromonocyclic compound / Aryl thioether / Azacycle / Benzenoid / Carbonyl group / Carboxylic acid show 18 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- E0YMX3S4JD
- CAS number
- 495399-09-2
- InChI Key
- MRWFZSLZNUJVQW-DEOSSOPVSA-N
- InChI
- InChI=1S/C25H29NO4S/c1-4-29-24(25(27)28)17-19-6-10-21(11-7-19)30-16-15-26-18(2)5-14-23(26)20-8-12-22(31-3)13-9-20/h5-14,24H,4,15-17H2,1-3H3,(H,27,28)/t24-/m0/s1
- IUPAC Name
- (2S)-2-ethoxy-3-[4-(2-{2-methyl-5-[4-(methylsulfanyl)phenyl]-1H-pyrrol-1-yl}ethoxy)phenyl]propanoic acid
- SMILES
- CCO[C@@H](CC1=CC=C(OCCN2C(C)=CC=C2C2=CC=C(SC)C=C2)C=C1)C(O)=O
References
- General References
- Not Available
- External Links
- PubChem Compound
- 60151560
- PubChem Substance
- 347829238
- ChemSpider
- 32079086
- ChEBI
- 134708
- ChEMBL
- CHEMBL4297530
- PDBe Ligand
- EWR
- Wikipedia
- Saroglitazar
- PDB Entries
- 6lxb / 6lxc / 7e0a
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data4 Recruiting Treatment (NAFLD) / Dyslipidemia / Obesity / Syndrome, Metabolic / Type 2 Diabetes Mellitus 1 somestatus stop reason just information to hide 3 Recruiting Treatment Primary Biliary Cholangitis 1 somestatus stop reason just information to hide 3 Unknown Status Treatment (NAFLD) 1 somestatus stop reason just information to hide 3 Unknown Status Treatment Fatty Liver 1 somestatus stop reason just information to hide 2 Active Not Recruiting Treatment Fibrosis / Steatohepatitis, Nonalcoholic 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet Oral 4.000 mg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00149 mg/mL ALOGPS logP 5.05 ALOGPS logP 5.53 Chemaxon logS -5.5 ALOGPS pKa (Strongest Acidic) 3.73 Chemaxon pKa (Strongest Basic) -4.1 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 60.69 Å2 Chemaxon Rotatable Bond Count 11 Chemaxon Refractivity 126.09 m3·mol-1 Chemaxon Polarizability 48.69 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-0007-0009100000-04c181fe4eec22b4eff8 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-01ta-9508100000-ccbf294178681115c594 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-0ugs-0219000000-c7d958dfd14ab2761dd4 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-0m07-9224000000-47b302e2a3fe4f864248 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-001i-0951000000-f6ab8b4750d21c74d391 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-0fus-3933100000-fc7ae579743d72ff5cf2 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 219.9425958 predictedDarkChem Lite v0.1.0 [M-H]- 190.9334 predictedDeepCCS 1.0 (2019) [M+H]+ 222.3717958 predictedDarkChem Lite v0.1.0 [M+H]+ 193.29137 predictedDeepCCS 1.0 (2019) [M+Na]+ 220.4953958 predictedDarkChem Lite v0.1.0 [M+Na]+ 199.43646 predictedDeepCCS 1.0 (2019)
Drug created at October 21, 2016 03:20 / Updated at September 28, 2023 05:48